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Abstract: Thymidylate synthase (TYMS) is a crucial enzyme for DNA synthesis. TYMS expression is
regulated by its antisense mRNA, ENOSF1. Disrupted regulation may promote uncontrolled DNA
synthesis and tumor growth. We sought to replicate our previously reported association between
rs495139 in the TYMS-ENOSF1 3′ gene region and increased risk of mucinous ovarian carcinoma
(MOC) in an independent sample. Genotypes from 24,351 controls to 15,000 women with invasive
OC, including 665 MOC, were available. We estimated per-allele odds ratios (OR) and 95% confidence
intervals (CI) using unconditional logistic regression, and meta-analysis when combining these data
with our previous report. The association between rs495139 and MOC was not significant in the
independent sample (OR = 1.09; 95% CI = 0.97–1.22; p = 0.15; N = 665 cases). Meta-analysis suggested
a weak association (OR = 1.13; 95% CI = 1.03–1.24; p = 0.01; N = 1019 cases). No significant association
with risk of other OC histologic types was observed (p = 0.05 for tumor heterogeneity). In expression
quantitative trait locus (eQTL) analysis, the rs495139 allele was positively associated with ENOSF1
mRNA expression in normal tissues of the gastrointestinal system, particularly esophageal mucosa
(r = 0.51, p = 1.7 × 10−28), and nonsignificantly in five MOC tumors. The association results, along
with inconclusive tumor eQTL findings, suggest that a true effect of rs495139 might be small.
Keywords: consortia; enolase superfamily member 1; expression quantitative trait locus; genetics;
gynecology; ovarian neoplasms; single-nucleotide polymorphism; thymidylate synthase
1. Introduction
Ovarian carcinomas of mucinous histology (MOC) are an uncommon type of ovarian cancer
characterized by intracellular mucin deposits and relatively favorable prognosis when diagnosed at
early stage [1]. Few epidemiologic risk factors are known for these cancers, and the standard risk
factors for other types of ovarian cancer do not seem to apply [2]. Increased risk has been associated
with current or recent smoking, a higher number of pack years of smoking [3,4], and with increased
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body mass index [5]. Recently, we reported the first genome-wide significant-susceptibility alleles for
MOC at 2q13, 2q31.1, and 19q13.2 [6], and at 3q22.3 and 9q31.1 [7].
Thymidylate synthase (TYMS) is a crucial enzyme for DNA synthesis in both normal and tumor
cells. It catalyzes the transformation of dUMP to dTMP and is the only de novo source of thymidylate
for pyrimidine biosynthesis [8]. Consequently, it is an important chemotherapy target. We previously
found an association between the rs495139 single-nucleotide polymorphism (SNP) and increased risk
of MOC (odds ratio (OR) = 1.91; 95% confidence interval (CI) = 1.10–3.31; p = 0.02; N = 80 MOC cases)
(unpublished) in an earlier genotyping project [9] that we subsequently confirmed (hereto referred to
as “discovery” sample) (OR = 1.32; 95% CI = 1.07–1.62; p = 0.02; N = 354 MOC cases) [10]. This SNP is
located downstream of the 3′ untranslated region (UTR) of TYMS (Entrez Gene ID 7298) and situated
intronic to the enolase superfamily member 1 (ENOSF1, Entrez Gene ID 55556) gene on chromosome
18. ENOSF1 encodes an antisense transcript that downregulates TYMS gene expression [11–13].
We hypothesized that genetic polymorphisms could perturb the TYMS mRNA-antisense mRNA
autoregulatory complex by either increasing TYMS or decreasing ENOSF1 gene expression to promote
uncontrolled DNA synthesis and tumor growth. Given the SNP’s potential functional role to regulate
TYMS expression and because TYMS is an important chemotherapy target, our objective was to
replicate the genetic association from our discovery sample [10] using a very large independent sample
of MOC from participating studies in the Ovarian Cancer Association Consortium (OCAC) that were
genotyped as part of the international Collaborative Oncology Gene-environment Study (iCOGS).
2. Results
2.1. Association Testing
There were 667 MOC cases and 15,941 controls in the independent iCOGS sample, but ORs could
not be estimated for four individual studies, resulting in 665 MOC cases and 15,256 controls evaluated
using the meta-analysis approach. The association between rs495139 and MOC in the iCOGS sample
was not significant (OR = 1.09; 95% CI = 0.97–1.22; p = 0.15; N = 665 cases) (Table 1). The meta-analysis
combining the iCOGS sample with the discovery sample [10] suggested an increased risk (OR = 1.13;
95% CI = 1.03–1.24; p = 0.01; N = 1019 cases) (Table 1). The between-group heterogeneity was low to
moderate for the discovery studies (I2 = 37.6), and low for the iCOGS studies (I2 = 0) and for all studies
in the meta-analysis (I2 = 14.9) (Figure 1). The ORs did not differ appreciably using a pooled-analysis
approach that combined all cases and controls from the discovery [10] and iCOGS samples into a single
dataset (OR = 1.12; 95% CI = 1.02–1.22; p = 0.02; N = 1021 cases) (Table 1). Thus, we proceeded with
additional analyses using the pooled data. rs495139 was not associated with ovarian cancer overall
or with the other histologic types (Table 1, p = 0.05 for tumor heterogeneity, 4 df). Because molecular
evidence suggests that many invasive MOC evolve along a multistep model of progression from benign
to atypical proliferative (borderline) epithelium [1] similar to colorectal cancer [14], we evaluated
the association between rs495139 and borderline MOC only (OR = 0.97; 95% CI = 0.86–1.09; p = 0.59,
N = 621) and with combined borderline and invasive MOC (OR = 1.06; 95% CI = 0.99–1.14; p = 0.11,
N = 1642 cases). The weakened associations suggested the SNP might contribute only to the invasive
phenotype. Women diagnosed with MOC had an earlier age at diagnosis (median age = 54 years)
than women with the more common serous histology (median age = 60 years). To assess whether
or not potentially different age distributions between MOC cases and controls influenced ORs, we
matched each case to within 5-year age categories to three controls, where possible, and performed an
age-stratified logistic regression. The OR was slightly larger (seven cases could not be matched due to
young age of diagnosis): OR = 1.16 (95% CI = 1.04–1.28; p = 0.006; N = 1013 cases and 3014 controls)
when the median age was similar (54 years for cases and 54.7 years for controls).
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Table 1. Associations 1 between rs495139 and ovarian carcinoma among European subjects.
Study Sample and Tumor Histology Analysis Method Cases, N Controls, N OR 95% CI p-Value
iCOGS sample
Mucinous invasive only Meta-analysis 665 2 15,256 2 1.09 0.97–1.22 0.16
Discovery + iCOGS samples
Mucinous invasive only Meta-analysis 1019 2 23,666 2 1.13 1.03–1.24 0.01
All invasive tumors 3 Pooled 15,000 24,351 1.00 0.97–1.03 0.84
Mucinous invasive only Pooled 1021 2 24,351 1.12 1.02–1.22 0.02
Mucinous borderline Pooled 621 24,351 0.97 0.86–1.09 0.59
Mucinous invasive and borderline combined Pooled 1642 24,351 1.06 0.99–1.14 0.11
Serous invasive Pooled 8889 24,351 1.01 0.98–1.05 0.53
Endometrioid invasive Pooled 2164 24,351 0.97 0.91–1.04 0.40
Clear cell invasive Pooled 1046 24,351 0.93 0.85–1.02 0.11
iCOGS, International Collaborative Oncology Gene-environment Study. 1 Studies in the meta-analysis were
restricted to non-Hispanic whites (Discovery set), as in the original report [10], or adjusted for European ancestry
using principal components analysis (iCOGS). Studies in the pooled analysis were also adjusted for study set. 2 Two
studies (HAW and STA) in iCOGS each contributed one mucinous ovarian carcinoma (MOC) case and two studies
(NHS and MSK) did not contribute any MOC cases in iCOGS; therefore, odds ratios could not be calculated for
these four studies and these subjects (HAW: 1 MOC case, 17 controls; STA: 1 MOC case, 6 controls; NHS: 0 MOC
cases, 69 controls; MSK: 0 MOC cases, 593 controls) were dropped from the meta-analysis but were retained in the
pooled analysis. 3 Includes invasive tumors with the following histology: serous; mucinous; endometrioid; clear
cell; mixed cell; other specified epithelial ovarian cancer; undifferentiated or poorly differentiated epithelial; and
unknown histology but known to be epithelial.
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Figure 1. Forest plot of the study-specific (filled diamonds) and pooled (open diamonds) odds ratios
and 95% confidence intervals (solid horizontal lines) for the association between rs495139 and risk of
MOC under the ordinal genetic risk model in the discovery and iCOGs samples. The total sample size
in the meta-analysis is 1019 MOC cases and 23,666 controls of European ancestry. Dashed vertical line
represents overall summary estimate–odds ratio. Individual study estimates are adjusted for ancestry
and pooled estimates are adjusted for ancestry and study. See Table 1 footnote for details regarding
sample size.
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2.2. Expression Quantitative Trait Locus (eQTL) Analysis
We tested for eQTL association between rs495139 genotypes and gene expression in normal tissues
in the Genotype Tissue Expression (GTEx) project. The most significant eQTL was with increased
ENOSF1 mRNA expression in normal esophagus mucosa (r = 0.51, p = 1.7× 10−28) (Figures S1 and S2).
There was no reported association with TYMS mRNA expression in esophageal mucosa. In 316 women
with ovarian cancer (five were MOC tumors), eQTL analysis between germline genotypes of rs495139
and tumor gene expression showed positive associations for two probes targeting ENOSF1 (P15906:
beta = 0.17, p = 0.03, and P4503: beta = 0.15, p = 0.05) but not with the probe targeting TYMS (P50096:
beta = 0.12, p = 0.12) (Table S1). Among the five MOC tumors, we observed positive eQTL associations
with one probe targeting ENOSF1 (P4503: beta = 0.87, p = 0.32) but not the other (P15906: beta = 0.08,
p = 0.94) and an inverse eQTL association with the probe targeting TYMS (P50096: beta = −0.70,
p = 0.45) but none were statistically significant given the small sample size.
3. Discussion
We previously observed a statistically significant risk association of rs495139 [10], which was not
replicated by this larger analysis of MOC. Combining the two independent datasets of 1019 MOC
samples suggested a weakly positive association between rs495139 and risk of MOC, particularly in
age-matched analysis. The association observed from the combined analysis was attenuated with the
inclusion of borderline cases.
Few genetic risk factors for MOC are known. We previously published results from two
genome-wide association studies (GWAS) reporting five susceptibility variants for MOC at 2q13,
2q31.1, 19q13.2 [6], 3q22.3, and 9q31.1 [7]. The likelihood that the candidate SNP rs495139 is a genetic
risk factor for MOC is small. Since the time of preparing this manuscript, we conducted a third,
larger GWAS of ovarian cancer [7], which included many of the participants in the current report.
Results from that GWAS also do not support significant associations between rs495139 and invasive
MOC (OR = 0.93; 95% CI = 0.86–1.01; p = 0.07, 1417 cases) or combined borderline and invasive
MOC (OR = 0.97; 95% CI = 0.91–1.03; p = 0.29, 2566 cases). Our results suggest the previously
published significant association [10] was likely driven by heterogeneity from a few studies with
extreme ORs and that balanced age matching between MOC cases and controls might reduce some
bias. A strong functional influence of rs495139 on increased ENOSF1 gene expression was found
in GTEx normal gastrointestinal tissues and, in particular, esophageal mucosa. This is interesting
because the origin of normal tissue from which MOC arises is unclear but may be similar to the
mucosa of the gastrointestinal system [1,15]. For example, small array-based studies (N = 3 to 9) of
MOC relate them more closely to colonic epithelium or colorectal cancers than to normal ovarian
surface epithelium [15,16]. Further, some MOC may arise from a morphologically analogous transition
observed in gastroesophageal adenocarcinoma. The metaplasia seen in MOC is a change in cell
type from a monolayer of normal nondescript, poorly differentiated mesothelial cells [17] to a single
layer of tall, columnar epithelial cells with mucin-containing cytoplasm [18]. This is analogous to the
metaplasia seen in the development of Barrett’s esophagus, the precursor lesion to gastroesophageal
adenocarcinoma, where there is a change in cell type from a flat squamous cell layer to columnar-like
epithelium with visible mucus [19]. We also observed a nonsignificant but positive eQTL association
between rs495139 and a probe for ENOSF1 mRNA in MOC, as well as an inverse eQTL association
between rs495139 and TYMS mRNA in MOC tumors, which contradicts our hypothesis that rs495139
might decrease ENOSF1 antisense mRNA to possibly increase TYMS mRNA availability for DNA
synthesis and tumor growth. The small number of MOC tumors in this eQTL analysis precluded any
definitive interpretation of results. Given that TYMS is a chemotherapy target, an rs495139-associated
increase in ENOSF1 and decrease in TYMS expression might suggest a favorable tumor profile for
patient survival.
This investigation was strengthened by including large numbers of women with MOC that
contributed individual genotype data in iCOGS and by the ability to conduct an age-matched analysis
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to control for differences in the distribution of age among cases and controls, which could potentially
bias associations. A further advantage was our centralized genotyping and rigorous quality-control
standards. We were also able to query data in silico as well as in women with corresponding germline
SNP and tumor gene expression data from the Mayo Clinic in order to provide contextual information
on potential functional influences between genotypes and tumor gene expression.
In summary, the evidence in this study to support a role of rs495139 in the TYMS-ENOSF1 region
as a genetic risk factor for MOC is weak and suggests that any true effect is likely to be small.
4. Materials and Methods
4.1. Study Subjects and Genotyping
Subjects (n = 47,630) represented multiple individual studies participating in the OCAC [20].
Informed consent was obtained in individual studies and local human research investigation
committees approved each study. TYMS-ENOSF1 rs495139 was genotyped on an Illumina Infinium
custom iSelect BeadChip developed for the iCOGS (Beadchip) [21]. Among 44,634 subjects whose
DNA passed centralized genotyping quality-control criteria [20], the call rate for rs495139 was 99.98%.
We restricted the analysis to subjects with European ancestry and invasive tumors, leaving 37,792
eligible subjects. Of these, the effect allele frequency (EAF) among 23,444 controls was 0.41 and no
departure from Hardy–Weinberg equilibrium was seen (p = 0.32).
To obtain the independent sample (referred to as the “iCOGS” sample), we excluded genotypes
in iCOGS from women who were in our earlier analysis [10] (referred to as the “discovery” sample).
Individual-level genotypes were available on 10,019 invasive ovarian cancer cases (667 with invasive
MOC) and 15,941 controls from 31 studies in iCOGS for replication analysis. We also re-evaluated
the rs495139 association by combining genotypes from the iCOGS sample with the discovery sample
(4981 invasive ovarian cancer cases, of which 354 were invasive MOC, and 8410 controls from 14 OCAC
studies) [10], resulting in a total of 15,000 invasive ovarian cancer cases (1021 with invasive MOC) and
24,351 controls (Table S2). This larger sample allowed additional subset analyses to be performed.
4.2. In Silico and eQTL Analysis
We used the GTEx project portal (V7 data release, 18 September 2017) [22] for in silico eQTL
analysis between rs495139 and TYMS and ENOSF1 gene expression in 10,294 eQTL normal tissues
representing over 50 different tissue types. We evaluated eQTL between rs495139 genotypes
from lymphocytes with gene expression from patient-matched tumors among 316 women with
ovarian cancer (including five MOC tumors) from the Mayo Clinic. Gene expression was assessed
using a 4 × 44 K Agilent array (Agilent Technologies, Santa Clara, CA, USA) and measured as
log2(tumor/reference) probe intensity signals as described previously [23] based on a mixed tumor
cell-type reference of 104 tumor samples, including papillary serous (n = 67), endometrioid (n = 5),
mucinous (n = 3), clear cell (n = 3), malignant mixed Müllerian tumor (n = 5), goblet cell (n = 1),
squamous (n = 1), transitional cell (n = 1), benign (n = 4), normal (n = 7), and unknown epithelial
(n = 7). Analyses included one Agilent probe for TYMS (P50096) and two probes for ENOSF1 (P15906
and P4503).
4.3. Statistical Analysis
ORs and 95% CIs were estimated using unconditional logistic regression assuming an ordinal
(log-additive) genetic model and adjusting for study and for the first five eigenvalues from principal
components analysis to account for substrata of European ancestry [20]. Using fixed-effects
meta-analysis, we combined study-specific effect estimates from our previous report [10] with
study-specific effect estimates from unique iCOGS subjects using the inverse-variance method to
weight the overall summary OR. The degree of statistical heterogeneity between studies was estimated
by I2, the between-group variance [24]. Studies with statistically homogeneous ORs yield an I2 value
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of zero. ORs were derived for ovarian cancers overall and simultaneously for the different histologic
types (serous, mucinous, endometrioid, and clear cell) using polytomous logistic regression. Statistical
heterogeneity of the SNP-ovarian carcinoma histology associations was tested using the type 3 analysis
of effects with 4 degrees of freedom [25]. Van der Waerden rank transformation was applied to tumor
gene expression values from the Agilent array, adjusting for age in linear regression and treating the
number of variant alleles carried as ordinal on the log-additive scale. Statistical tests were two-sided
and implemented with SAS version 9 (SAS Institute, Cary, NC, USA). Meta-analysis was performed
with Stata/SE (version 13.1, StataCorp, College Station, TX, USA).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/9/
2473/s1.
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